Ascendis Pharma (ASND1N) Stock Statistics & Valuation Metrics
Total Valuation
Ascendis Pharma has a market cap or net worth of MXN 294.54B. The enterprise value is MXN 17.81B.
- Market Cap
- MXN 294.54B
- Enterprise Value
- MXN 17.81B
Share Statistics
Ascendis Pharma has 62,376,846 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 62,376,846
- Owned by Insiders
- 0.02%
- Owned by Institutions
- 41.36%
Financial Efficiency
Ascendis Pharma’s return on equity (ROE) is 1.35 and return on invested capital (ROIC) is -18.19%.
- Return on Equity (ROE)
- 1.35
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -18.19%
- Return on Capital Employed (ROCE)
- -0.56
- Revenue Per Employee
- 581.76K
- Profits Per Employee
- -184.22K
- Employee Count
- 1,189
- Asset Turnover
- 0.53
- Inventory Turnover
- 0.34
Valuation Ratios
The current PE Ratio of Ascendis Pharma is 18.57. Ascendis Pharma’s PEG ratio is 0.03.
- PE Ratio
- 18.57
- PS Ratio
- 14.02
- PB Ratio
- 10.07
- Price to FCF
- 43.88
- Price to Operating Cash Flow
- 41.15
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Ascendis Pharma had revenue of 691.71M and earned -219.03M in profits. Earnings per share was -3.62.
- Revenue
- 691.71M
- Gross Profit
- 588.53M
- Operating Income
- -130.89M
- Pretax Income
- -204.26M
- Net Income
- -219.03M
- EBITDA
- -109.80M
- Earnings Per Share (EPS)
- -3.62
Cash Flow
In the last 12 months, operating cash flow was 351.32M and capital expenditures -14.43M, giving a free cash flow of 336.90M billion.
- Operating Cash Flow
- 351.32M
- Free Cash Flow
- 336.90M
- Free Cash Flow per Share
- 5.24
Dividends & Yields
Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.28%
- Earnings Yield
- 5.23%
Stock Price Statistics
- Beta
- -0.01
- 52-Week Price Change
- 12.78%
- 50-Day Moving Average
- 4354.49
- 200-Day Moving Average
- 4046.90
- Relative Strength Index (RSI)
- 6.49
- Average Volume (3m)
- 192
Important Dates
Ascendis Pharma upcoming earnings date is Nov 11, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 11, 2026
- Ex-Dividend Date
- ―
Financial Position
Ascendis Pharma as a current ratio of 1.04, with Debt / Equity ratio of -535.43%
- Current Ratio
- 1.04
- Quick Ratio
- 0.76
- Debt to Market Cap
- 0.08
- Net Debt to EBITDA
- -2.33
- Interest Coverage Ratio
- -1.69
Taxes
In the past 12 months, Ascendis Pharma has paid 14.78M in taxes.
- Income Tax
- 14.78M
- Effective Tax Rate
- -0.07
Enterprise Valuation
Ascendis Pharma EV to EBITDA ratio is 184.60, with an EV/FCF ratio of 42.81.
- EV to Sales
- 13.68
- EV to EBITDA
- 184.60
- EV to Free Cash Flow
- 42.81
- EV to Operating Cash Flow
- 41.05
Balance Sheet
Ascendis Pharma has MXN 811.92M in cash and marketable securities with MXN 449.89M in debt, giving a net cash position of MXN 362.04M billion.
- Cash & Marketable Securities
- MXN 811.92M
- Total Debt
- MXN 449.89M
- Net Cash
- MXN 362.04M
- Net Cash Per Share
- MXN 5.80
- Tangible Book Value Per Share
- MXN 22.26
Margins
Gross margin is 90.19%, with operating margin of 10.38%, and net profit margin of 71.69%.
- Gross Margin
- 90.19%
- Operating Margin
- 10.38%
- Pretax Margin
- 9.59%
- Net Profit Margin
- 71.69%
- EBITDA Margin
- 7.41%
- EBIT Margin
- 5.73%
Analyst Forecast
The average price target for Ascendis Pharma is MXN 5,858.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- MXN 5,858.70
- Price Target Upside
- 40.65% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 19
- Revenue Growth Forecast
- 106.21%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 10
- AI Score
- ―
